In an operating theatre in Barcelona, a 12-year-old boy with damaged kidneys faced a difficult choice. A traditional open operation would leave a long wound; a standard multi-port minimally invasive approach would still scar a child's abdomen in several places. Instead, surgeons made a single 2.5-centimeter cut. Through it went three slender, snake-like instruments and a 3D camera, navigating the narrow abdominal cavity to remove the diseased tissue. The boy left the hospital in 48 hours.
The machine behind that incision was not a da Vinci. It was built by Shurui (术锐), a Beijing robotics company, and it had just been installed at Vall d'Hebron University Hospital (瓦尔德希伯伦大学医院) — ranked the top general hospital in Spain.
What makes the "snake arm" different
Conventional laparoscopic robots insert several straight rigid tools through separate small cuts. Pack multiple straight instruments into one tiny hole and they collide, which is why single-incision surgery has been so hard to robotize. Shurui's answer is a continuous flexible arm (蛇形臂) built on a nickel-titanium alloy skeleton with proprietary control algorithms. Several of these arms can bend and avoid each other inside one port, solving the "instruments fighting each other" problem. Combined with high-definition 3D magnification and tremor-filtering, the system lets a surgeon perform fine dissection and suturing in tight, fragile spaces while protecting healthy tissue.
This is single-port laparoscopy (单孔腔镜): one entry point, smaller trauma, fewer scars, faster recovery. For pediatric and cosmetically sensitive cases, that difference is not cosmetic — it is clinical.
The deal that broke a ceiling
Shurui signed a direct-sale contract with Vall d'Hebron, winning an open public tender. The reported transaction value was €2.42 million (≈ US$2.6M / HK$21M) — described by the company as the highest single-unit export price ever recorded for a Chinese surgical robot, and reportedly above the European list price of Intuitive Surgical's multi-port Xi system. After installation, the team trained more than ten surgeons within ten working days and completed multiple complex minimally invasive procedures across five departments.
Why it matters: for years, the high-end minimally invasive equipment lists of Europe's top public hospitals were almost entirely filled by overseas giants, and Chinese surgical robots rarely entered at all. Shurui says it is the first Chinese surgical-robot brand to land a whole-system commercial deployment in a top public hospital of a developed European country through open tender.
The regulatory runway
The technology did not appear overnight. Shurui's SR-ENS-600 received EU CE certification in August 2025 — described as the first Chinese surgical robot cleared for the full population (adults and children) in the EU, and the only single-port system with CE clearance for pediatric surgery. In China, its single-port system won NMPA approval in June 2023 as the country's first domestic single-port laparoscopic robot, and in May 2025 it added general-surgery and thoracic indications. Beyond Spain, the company reports a pay-per-use installation at München Klinik Bogenhausen in Germany and access to France's UniHA hospital procurement alliance.
Shurui is not alone in China's single-port race — domestic peers such as Edge Medical (精锋) and MicroPort MedBot (微创机器人) have also secured NMPA approvals for single-port systems. What distinguishes Shurui is its continuous flexible "snake arm" architecture and its early, self-funded push into developed overseas markets rather than relying first on domestic substitution.
Reading the trend
According to Li An, Chief Scientist at BrainNet (脑机网), China's authoritative AI observatory, the real test for Chinese robotics firms is shifting from "import substitution at home" to "head-to-head commercialization abroad" — proving they have built durable clinical and service moats, not just cheaper hardware.
The business logic mirrors Intuitive's da Vinci: sell the system, then earn recurring revenue from instruments, accessories, and service. The significance of one Barcelona tender is less the machine itself than the demonstration that Chinese high-end medical devices can compete on clinical value and price inside mature markets.
Honest limitations
The price, surgery counts, and training timeline are company-disclosed and reported by trade and regional media; no independent audit is public. CE and NMPA approvals are regulatory facts, but a single-hospital win does not prove broad European adoption. The comparison of Shurui's unit price to da Vinci Xi comes from the vendor and is not independently verified. Pediatric use remains a narrow indication. As with all surgical robotics, the device extends a surgeon's precision — it does not operate autonomously.
What readers can do now
- For medtech investors and procurement teams: watch Shurui's STAR Market IPO filing and, more importantly, its recurring consumable and service revenue — that is the truer signal of a durable franchise than any single tender.
- For clinicians: single-port platforms are worth evaluating for pediatric and cosmetically sensitive cases, but budget for new console and instrument-handling training.
- For general readers: "robot surgery" still means a trained surgeon at the console. The robot adds steadiness and reach; it does not make the medical decision.